1. Home
  2. ANTA vs ACOG Comparison

ANTA vs ACOG Comparison

Compare ANTA & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANTA

Antalpha Platform Holding Company Ordinary Shares

HOLD

Current Price

$3.64

Market Cap

182.1M

Sector

Finance

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$7.92

Market Cap

185.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANTA
ACOG
Founded
2022
2000
Country
Singapore
Canada
Employees
113
71
Industry
Investment Bankers/Brokers/Service
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
182.1M
185.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ANTA
ACOG
Price
$3.64
$7.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$16.17
$16.00
AVG Volume (30 Days)
3.3K
92.2K
Earning Date
06-16-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$21.95
$139.22
Revenue Next Year
$30.46
$134.48
P/E Ratio
$19.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.42
$4.50
52 Week High
$13.82
$10.14

Technical Indicators

Market Signals
Indicator
ANTA
ACOG
Relative Strength Index (RSI) 21.54 56.70
Support Level N/A $5.27
Resistance Level $9.81 $8.80
Average True Range (ATR) 0.39 0.56
MACD -0.01 -0.08
Stochastic Oscillator 10.73 40.74

Price Performance

Historical Comparison
ANTA
ACOG

About ANTA Antalpha Platform Holding Company Ordinary Shares

Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: